Studies related to COVID-19 Severity and Curcumin

Nano-curcumin Therapy, A Promising Method In Modulating Inflammatory Cytokines In COVID-19 Patients

Effect Decrease
Values Compared placebo, nano-curcumin significantly lowered levels of IL-1-beta and IL-6 and improved clinical symptoms such as cough, fever, and dyspnea.
Trial Design Randomized trial
Trial Length 1-2 Weeks
Number of Subjects 40
Sex n/a
Notes for this study:
In this trail, patients who were newly diagnosed with COVID-19 received either 160 mg nano-curcumin (40 mg capsules taken 4 times per day) or placebo for 14 days. The outcomes measured were blood levels of IL-1-beta, IL-6, IL-18, and TNF-alpha, as well as the patient's clinical signs and symptoms.